このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Elutia 将来の成長

Future 基準チェック /26

Elutiaは、33.6%と35.9%でそれぞれ年率33.6%で利益と収益が成長すると予測される一方、EPSはgrowで42.8%年率。

主要情報

33.6%

収益成長率

42.8%

EPS成長率

Biotechs 収益成長	24.5%
収益成長率	35.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	18 Jun 2024

今後の成長に関する最新情報

Recent updates

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Mar 10

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Feb 21

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Apr 17

Aziyo Biologics appoints Williams as Chief Scientific Officer

Aug 26

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aug 10

業績と収益の成長予測

NasdaqCM:ELUT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	71	-16	N/A	N/A	1
12/31/2025	39	-32	N/A	N/A	2
12/31/2024	28	-40	N/A	N/A	2
3/31/2024	25	-49	-19	-19	N/A
12/31/2023	25	-41	-22	-22	N/A
9/30/2023	51	-29	-18	-18	N/A
6/30/2023	51	-31	-19	-18	N/A
3/31/2023	19	-38	-20	-19	N/A
12/31/2022	24	-36	-22	-21	N/A
9/30/2022	28	-39	-23	-23	N/A
6/30/2022	34	-37	-21	-20	N/A
3/31/2022	46	-28	-18	-18	N/A
12/31/2021	47	-25	-16	-15	N/A
9/30/2021	49	-21	-15	-14	N/A
6/30/2021	49	-23	-13	-13	N/A
3/31/2021	46	-26	-16	-16	N/A
12/31/2020	43	-25	-14	-14	N/A
9/30/2020	42	-23	-12	-11	N/A
6/30/2020	42	-16	-12	-12	N/A
3/31/2020	43	-13	-10	-9	N/A
12/31/2019	43	-12	-8	-7	N/A
12/31/2018	39	-12	-6	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ELUT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ELUT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ELUT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ELUTの収益 ( 35.9% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ELUTの収益 ( 35.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ELUTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Elutia 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 60% to US$8.00

Consensus revenue estimates increase by 17%

Consensus revenue estimates increase by 12%, EPS downgraded

Consensus revenue estimates decrease by 25%, EPS upgraded

Price target decreased by 17% to US$10.00

Aziyo Biologics, Inc. Provides Preliminary Sales Guidance for the Fourth Quarter and Full Year 2022

Recent updates

Price target increased by 60% to US$8.00

Elutia Inc. Announces FDA Clearance of EluPro®

Co-Founder exercised options and sold US$67k worth of stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Elutia Inc. to Report Q1, 2024 Results on May 09, 2024

New major risk - Shareholder dilution

Elutia Inc., Annual General Meeting, Jun 06, 2024

New major risk - Shareholder dilution

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Elutia Inc. to Report Q4, 2023 Results on Mar 07, 2024

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance

Consensus revenue estimates increase by 17%

Elutia Notifies the Nasdaq Stock Market LLLC That the Company Was Not in Compliance with Listing Rule 5605(B)(1)

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Berkeley Biologics, LLC completed the acquisition of Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT).

Elutia Inc. Receives A Delisting Determination Letter from Listing Qualifications Department of Nasdaq

Elutia Inc. to Report Q3, 2023 Results on Nov 13, 2023

Elutia Inc. announced that it has received $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC

New major risk - Shareholder dilution

Berkeley Biologics, LLC entered into an Asset Purchase Agreement Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT) for $35 million.

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates decrease by 25%, EPS upgraded

Aziyo Biologics, Inc. Announces the Voluntary Recall of Its Viable Bone Matrix Products

Price target decreased by 17% to US$10.00

Aziyo Biologics, Inc. Presents Positive Clinical Data on Cangaroo® Biologic Envelope

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.60 loss in 1Q 2022)

Aziyo Biologics, Inc. to Report Q1, 2023 Results on May 10, 2023

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Full year 2022 earnings released

Aziyo Biologics, Inc. Provides Preliminary Sales Guidance for the Fourth Quarter and Full Year 2022

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. Revises Revenue Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Aziyo Biologics, Inc. Appoints David Colpman to Board of Directors and Audit Committee

Aziyo Biologics, Inc. Promotes Jeff Hamet to Senior Vice President of Finance

Aziyo Biologics, Inc. Appoints Michelle Leroux Williams, Ph.D as Chief Scientific Officer

Aziyo Biologics appoints Williams as Chief Scientific Officer

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Announces Randal Mills as Chief Executive Officer

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aziyo Biologics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Aziyo Biologics, Inc. Appoints C. Randal (Randy) Mills, Ph.D. as Interim President

Aziyo Biologics Receives a Written Notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Continued Listing Requirement Under Nasdaq Listing Rule 5450(b)(1)(A)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Confirms Financial Guidance for Year 2022

Price target decreased to US$13.00

Aziyo Biologics, Inc. to Report Q1, 2022 Results on May 09, 2022

Aziyo Biologics, Inc., Annual General Meeting, Jun 07, 2022

Aziyo Biologics, Inc. Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics

Consensus EPS estimates fall by 10%

Aziyo Biologics, Inc. Provides Net Sales Guidance for the Full Year 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Aziyo Biologics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Aziyo Biologics, Inc. announced that it has received $13.999976 million in funding

Aziyo Biologics, Inc. announced that it expects to receive $13.999976 million in funding

Aziyo Biologics Receives Notice from Nasdaq Stating Non Compliance with Nasdaq Listing Rule 5450(B)(1)(A)

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$15.79 loss in 3Q 2020)

Price target decreased to US$15.00

Price target decreased to US$15.75

業績と収益の成長予測

アナリストによる今後の成長予測